News
18h
GlobalData on MSNTariffs driving supply chain localisation and automationLocalising and automating supply chains will allow companies to mitigate the impact of tariffs and minimise resulting costs.
1h
Al Jazeera on MSNTesla finally parks in India. But can it survive?Elon Musk’s EV giant has launched its Model Y in Mumbai, but its $70,000 price tag may be its biggest speed bump.
Following today’s release of DFS’ figures for the 52 weeks ending 29 June 2025; Matt Walton, senior retail analyst at ...
The Trump administration has already collected a huge sum from tariffs since initiating a global trade war in April.
18h
GlobalData on MSNGrenke becomes 40th member of Acquis Lumia platformGrenke has become the 40th organisation to join Acquis Lumia, an industry-wide register of asset finance borrowing created to ...
The success of the post-growth model is reliant on transparency, clear and honest communication with customers and supplier collaboration.
Walmart and its banking partner Mastercard have created a new payment system for international money transfers, data ...
Experian (EXPN), Barratt Redrow (BTRW), B&M European Value (BME), GlobalData (DATA), Robert Walters (RWA), Mobico (MCG), ...
6d
GlobalData on MSNNvidia’s historic $4 trillion market cap highlights AI chip sectorAccording to GlobalData’s Innovation Radar report, “AI Chips – Trends, Market Dynamics and Innovations,” the global AI chip ...
2d
Medical Device Network on MSNMedtronic’s Hugo robot wins CE mark for vessel-sealing technologyMedtronic has secured EU CE mark approval for LigaSure RAS, a vessel-sealing instrument for use with the company’s Hugo robotic-assisted surgery (RAS) system.
2d
GlobalData on MSNCaranx Medical’s AI TAVI-TAVR software gains FDA approvalThe US Food and Drug Administration (FDA) has cleared Caranx Medical’s TAVIPILOT Soft, an artificial intelligence (AI)-based guide software for use during Transcatheter Aortic Valve Implantation (TAVI ...
6d
GlobalData on MSNPfizer and Astellas’ Xtandi improves OS as combination therapyPfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with nmHSPC, but only as a combination therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results